Neovascular (wet) age-related macular degeneration (AMD)
Conditions
Brief summary
Number of intravitreal injections after two years
Detailed description
Best-corrected visual acuity (BCVA), distance ETDRS and near LIX., Macular thickness (Central Retinal Thickness; CRT, in μm., Intraocular pressure (IOP) mmHg., Recurrence interval (maximum number of weeks from last injection to relapse), at first and last relapse., Durability (longest inactive interval detected, in number of weeks)., Cost efficiency: Quality-adjusted life years (QALY), cost-per-QALY is measured with the EuroQol-5 Dimension (EQ-5D) questionnaire., Vision-related quality of life (NEI VFQ-25)., Cost-benefit analysis: The incremental cost-effectiveness ratio (ICER).
Interventions
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
Sponsors
Vaestra Goetalandsregionen, Vaestra Goetalandsregionen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of intravitreal injections after two years | — |
Secondary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity (BCVA), distance ETDRS and near LIX., Macular thickness (Central Retinal Thickness; CRT, in μm., Intraocular pressure (IOP) mmHg., Recurrence interval (maximum number of weeks from last injection to relapse), at first and last relapse., Durability (longest inactive interval detected, in number of weeks)., Cost efficiency: Quality-adjusted life years (QALY), cost-per-QALY is measured with the EuroQol-5 Dimension (EQ-5D) questionnaire., Vision-related quality of life (NEI VFQ-25)., Cost-benefit analysis: The incremental cost-effectiveness ratio (ICER). | — |
Countries
Sweden
Outcome results
None listed